ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,283.40
0.00%
Dow Jones
38,571.03
0.00%
US Dollar vs MXN
17.8483
0.82%
Brent Oil
77.195
-1.21%
Bitcoin
69,356.02
0.80%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) Noticias

ESPR Esperion Therapeutics Inc

2.25
0.01 (0.45%)
Pre Mercado
Última actualización: 07:58:39
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Esperion Therapeutics Inc ESPR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.45% 2.25 07:58:39
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.24
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
28/5/202415:16EDGAR2Form 8-K - Current report
24/5/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202408:00GLOBEEsperion to Participate in Upcoming June Investor..
22/5/202407:00GLOBEFirst-In-Class Cholesterol-Lowering Treatment NILEMDO®..
20/5/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202405:00GLOBEBempedoic Acid Met Primary Endpoint of Phase 3 Trial in..
17/5/202414:08EDGAR2Form 144 - Report of proposed sale of securities
14/5/202407:00GLOBEEsperion Receives Five Year Patent Extension for Bempedoic..
10/5/202415:00GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
08/5/202415:31EDGAR2Form 8-K - Current report
07/5/202407:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202406:29EDGAR2Form 8-K - Current report
07/5/202405:00GLOBEEsperion Reports First Quarter 2024 Financial Results
29/4/202407:00GLOBEEsperion to Participate in Upcoming May Investor Conferences
23/4/202407:00GLOBEEsperion to Report First Quarter 2024 Financial Results on..
07/4/202413:45GLOBEEsperion Presents Important New Data from CLEAR Outcomes at..
01/4/202407:00GLOBEEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
26/3/202407:00GLOBEEsperion to Participate in 23rd Annual Needham Virtual..
25/3/202415:00GLOBEEsperion Announces Data from CLEAR Outcomes Sub-Groups as..
22/3/202417:26BWU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL®..
22/3/202414:10GLOBEU.S. FDA Approves Broad New Labels for NEXLETOL® and..
22/3/202410:04GLOBECHMP Issues Positive Opinions For Both Bempedoic Acid And..
27/2/202408:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:23EDGAR2Form 8-K - Current report
27/2/202405:00GLOBEEsperion Reports Fourth Quarter and Full Year 2023 Financial..
16/2/202415:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
14/2/202413:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202409:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202405:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202407:00GLOBEEsperion to Report Fourth Quarter and Full Year 2023..
01/2/202413:00GLOBERFK, Esperion Therapeutics Announce 2024 Promotional..
23/1/202415:00GLOBEEsperion Announces Closing of Public Offering of Common..
22/1/202405:10EDGAR2Form 8-K - Current report
22/1/202405:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/1/202420:15GLOBEEsperion Announces Pricing of $85.1 Million Public Offering..
18/1/202415:03EDGAR2Form 8-K - Current report
18/1/202415:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/1/202415:00GLOBEEsperion Announces Proposed Public Offering of Common Stock
11/1/202415:09EDGAR2Form 8-K - Current report
03/1/202414:15BWEsperion e Daiichi Sankyo Europe annunciano un emendamento..
03/1/202412:54BWEsperion et Daiichi Sankyo Europe annoncent une révision de..
03/1/202409:07BWEsperion und Daiichi Sankyo Europe geben Anpassung ihrer..
03/1/202407:00EDGAR2Form 8-K - Current report
03/1/202406:00GLOBEEsperion and Daiichi Sankyo Europe Announce $125 Million..
18/12/202307:00GLOBEEsperion to Participate in 42nd Annual J.P. Morgan..
13/12/202315:46DJNEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA..
13/12/202315:00GLOBEU.S. FDA Updates LDL-C Lowering Indication for Esperion’s..

Su Consulta Reciente

NASDAQ
ESPR
Esperion Therapeutics
LSE
QK69
Morg.st.b.v 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados